top of page

Zhimeng Biopharma Announces Global Partner Search for its' Development of Chronic Hepatitis B Cure

Shanghai, China and New York, USA, 1 March 2021 – Following a strategic review of its clinical and commercial development options, Zhimeng Biopharma (“Zhimeng”; has appointed The Sage Group (New York and London) to lead the partnering program for its leading drug candidate, ZM-H1505R.

Zhimeng is developing ZM-H1505R, a patented, orally-administered, investigational Hepatitis B Virus (HBV) capsid formation inhibitor, for treating patients with chronic hepatitis B (CHB) virus infection which afflicts 250 million people worldwide.